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Abstract 
Background: HLA‑G, a non‑classical HLA class I antigen, is of crucial interest during pregnancy by inhibiting mater‑
nal immune response. Its role during infections is discussed, and it has been described that high levels of soluble 
HLA‑G during childhood increase the risk of malaria. To explore more precisely interactions between soluble HLA‑G 
and malaria, latent class analysis was used to test whether distinct sub‑populations of children, each with distinctive 
soluble HLA‑G evolutions may suggest the existence of groups presenting variable malaria susceptibility.
Method: A study was conducted in Benin from 2010 to 2013 and 165 children were followed from birth to 
12 months. Evolution of soluble HLA‑G was studied by the latent class method.
Results: Three groups of children were identified: one with consistently low levels of soluble HLA‑G during follow‑up, 
a second with very high levels and a last intermediate group. In all groups, low birth weight, high number of malaria 
infections and high exposure to malaria transmission were associated with high level of soluble HLA‑G. Placental 
malaria was not. Presence of soluble HLA‑G in cord blood increased the probability of belonging to the highest 
trajectory.
Conclusion: These results, together with previous ones, confirm the important role of HLA‑G in the individual sus‑
ceptibility to malaria. Assaying soluble HLA‑G at birth could be a good indicator of newborns more fragile and at risk 
of infections during childhood.
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Background
Human Leukocyte Antigen-G (HLA-G) is a non-clas-
sical HLA class Ib antigen, with important immune-
regulatory functions [1], that differs from classical HLA 
class I antigens by a low amount of polymorphism and 
a tissue restricted expression [2, 3]. The physiologi-
cal HLA-G expression is restricted to fetal tissues such 
as invasive cytotrophoblast and amnion, and in adults, 
to immune-privileged organs, cornea, thymus, pancre-
atic islets, endothelial cell precursors, and erythroblasts. 
Dendritic cells and macrophages can also express HLA-G 
[4]. Seven alternative proteins can be generated, four 
membrane-bound and three secreted isoforms [3–5]. 
HLA-G is primarily expressed during pregnancy and 
plays an important role in maternal tolerance of the fetus. 
Trophoblast cells are protected by HLA-G which inhibit 
the cytolytic activity of NK cells and protect the semial-
logenic fetus from maternal rejections responses [4, 6, 7].
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Apart from pregnancy, HLA-G has been shown to be 
expressed in many types of tumours [8–11]. Tumour cells 
express HLA-G to escape to immunity and high levels of 
soluble HLA-G (sHLA-G) have been related with unfa-
vourable outcome of prognosis [12, 13]. In transplanta-
tion, HLA-G molecule has been shown to be important 
for a better allograft acceptance, whereas low serum lev-
els seem to increase the risk of autoimmunity [13, 14] and 
allergy [15]. If the role of HLA-G with viral infections is 
admitted [15–18], this association with parasite infec-
tions is much less documented [19, 20]. Recently, it was 
reported that genetic polymorphisms in HLA-G 3′UTR 
were associated with susceptibility to human African 
trypanosomiasis and could influence the clinical and 
immunological responses directed to Plasmodium falci-
parum [21–23].
A recent work reported that high levels of sHLA-G 
were significantly associated with a higher incidence 
ratio of malaria in Beninese children [24] consistent 
with the fact that the inhibition of immune responses 
by HLA-G expression could lead to a greater suscepti-
bility to malaria. In this previous analysis, hierarchical 
mixed models have been used to deal with the repeated 
measures design. However, mixed models make the 
assumption that individuals are randomly drawn from a 
homogeneous population. As a complement it seemed 
interesting to test whether distinct subpopulations of 
children are present in the overall population, each with 
its own parameters, with distinctive sHLA-G evolutions, 
or trajectories. The identification of trajectories of sHLA-
G through the first year of life and risk factors that pre-
dispose to, or modify, a particular trajectory may suggest 
the existence of individual with variable malaria suscep-
tibility. Latent class analysis (LCA) approach is ideally 
suited to explore this issue [25, 26].
Thus, the main objective of the present work was to 
explore the existence and characteristics of groups of 
children with different patterns of soluble HLA-G evolu-
tion between birth and 12  months of life in a cohort of 
Beninese children exposed to malaria, using latent class 
analysis.
Methods
Study design
The work is part of a research programme conducted in 
southern Benin. The protocol has been widely described 
elsewhere [24, 27] and will be presented below briefly.
Site description
The study included nine villages and three health centres: 
Tori Avamè, Tori Cada and Tori Gare, providing primary 
healthcare, and holding a maternity for antenatal care 
and childbirth. The study site was located in a malaria 
endemic area with an incidence rate of 16.9  % in 2013 
[28]. Malaria is transmitted mainly by Anopheles gambiae 
s.s. and Anopheles funestus [29]. P. falciparum is the most 
prevalent parasite and infectious peaks occur during the 
rainy season [28].
Study population
More than 600 pregnant women were included at deliv-
ery from June 2007 to July 2008; they did reside in the vil-
lages of the study and give birth in one of the three health 
centres. Twins, stillbirths and HIV-positive women were 
excluded. Newborns included were followed-up from 
birth to 12  months. Among them, 165 mother/infant 
pairs were selected based on the “placental infection” 
status of the mother at delivery. Placental infection was 
defined by the presence of asexual forms of P. falciparum 
in placental blood smears. Population was composed by 
the totality of mother/infant pairs with placental infec-
tion (n  =  51) and 114 randomly selected newborns 
whose mothers were not infected.
Data collection
Maternal characteristics and data on the course of the 
current pregnancy were documented through a ques-
tionnaire. At delivery, peripheral blood was sampled for 
soluble HLA-G and haemoglobin measurements. Thick 
and thin placental smears were performed to determine 
the existence of a placental P. falciparum infection. Cord 
blood was collected for soluble HLA-G measurements.
At birth, gestational age was estimated using Ballard 
method [30] and newborn were weighed. Monthly, thick 
blood smear (TBS) was systematically made (in absence 
of fever or other clinical sign) to detect asymptomatic 
malaria infection. Weekly, axillary temperature was 
measured by trained community health worker. In case 
of temperature higher than 37.5 °C, the child was lead to 
the health centre. A questionnaire was filled out and a 
TBS and a rapid diagnosis test (RDT) were made. Symp-
tomatic malaria cases were defined as fever (>37.5  °C) 
with RDT and/or TBS positive. TBS obtained monthly 
or during consultations were stained with Giemsa. Leu-
cocytes and parasites were counted simultaneously until 
leukocyte or parasite numbers reached 500. A TBS was 
declared negative if no parasite was found after count-
ing 500 leucocytes. TBSs were read by two laboratory 
technicians with less than 1  % disagreement. Malaria 
cases were treated with an artemisinin-based combina-
tion therapy (ACT), as recommended in Benin [31, 32]. 
In case of fever or any clinical sign, mothers were invited 
to bring their children to health centre where the same 
protocol was applied. At birth (in cord blood) and at 3, 
6, 9 and 12  months old, venous blood was sampled to 
quantify the level of sHLA-G. Finally, a time-dependent 
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environmental risk of exposure to malaria was assessed 
for each child by means of a statistical predictive model 
[33].
Variable of interest: soluble HLA‑G
Assays of sHLA-G have been made by ELISA method. 
Quantification of sHLA-G correspond to the soluble 
isoform HLA-G5 and HLA-G1 (after cleavage from the 
membrane-bound form). Techniques used for these 
manipulations are extensively described in another study 
[24]. Soluble HLA-G levels were used as a quantita-
tive variable (after logarithmic transformation) and as a 
dichotomic one (presence vs absence).
Covariates
From mothers, the following variables were used: Age; 
parity (primipare vs. multipare); placental malaria; ane-
mia (Hb level before delivery <11  g/dl) and sHLA-G in 
peripheral blood. From children: low birth weight (LBW) 
(<2500  g); preterm birth (gestational age <37  weeks of 
gestation); gender; number of malaria attacks during 
the follow-up (used as a quantitative variable, or binary 
variable with two groups: 0 or 1 vs. more than 1); envi-
ronmental risk of malaria (quantitative time-dependent 
variable, used as quartiles); sHLA-G level in cord blood 
and parasite density (PD defined as the number of P. fal-
ciparum per 100 leucocytes).
Statistical analysis
Latent class analysis was used to identify the sHLA-G 
level trajectories and assess their association with the 
covariates.
A general model’s formulation is:
where yit is the response variable (sHLA-G level of the 
ith children at age t), the βj are the coefficients associated 
to the children’s age in the jth group and the αj are the 
coefficients associated to covariates in the jth group (the 
index t specifies that the covariates can depend on time 
as the environmental risk of malaria) and εit the residual 
variation [εit ~ Ν (0, σ2)].
The posterior probability πj(zi) that a child i with 
the covariates vector zi belongs to the group j is: 
pij(zi) =
exp(ziθj)∑
j exp(ziθj)
 with covariates vector zi and its cor-
responding coefficients vector θj.
The analysis was performed using three steps.
Firstly, each sHLA-G trajectory has been modelled, 
by means of a polynomial function of time of degree 3, 
without introducing any covariate. The most appropriate 
number of trajectories was selected using the Bayesian 
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information criterion (BIC). The group prevalence, 
that should not be less than 5 % of the total number of 
the sample, was used as additional criteria, for practical 
interpretation [34].
Secondly, the effect of the covariates on each trajectory 
was studied using univariate and multivariate analysis. 
Only covariates associated with p < 0.20 during univari-
ate analysis were entered in the multivariate step. Statisti-
cal significance in the final model was set at p < 0.05. The 
effect of covariates on HLA-G trajectories can be iden-
tical for each trajectory or different according to them. 
During this step a particular attention was paid to the 
stability of the trajectories determined during the first 
step. Indeed, as mentioned by Nagin [35] the addition 
of significant covariates to the model should not widely 
modify the percentage of subjects in each trajectory.
In the final multivariate model each individual was 
assigned to the trajectory group for which he had the 
highest posterior probability. Within each group, poste-
rior probability values greater than or equal to 0.7 indi-
cate adequate internal reliability [36]. All these criteria 
allowed us to make a definitive choice of the appropriate 
number of classes.
Finally, in the third step, the predictor effect of some 
covariates to belong to one or more trajectory has been 
tested. This concerned placental malaria, parity, maternal 
anaemia, LBW and sHLA-G in cord blood.
All analyses were performed with the Stata® Software, 
Version 12 (StatCorp LP, College Station, TX, USA), 
using the syntax dedicated to generalized linear latent 
and mixed models (GLLAMM).
Ethics
The study’s protocol was approved by the Ethics Com-
mittee of the “Faculté des Sciences de la Santé (FSS)” of 
Cotonou and the “Institut de Recherche pour le Dével-
oppement (IRD)” Consultative Ethics Committee. All 
mothers and fathers were informed during antenatal 
care visits and meetings conducted in villages before the 
beginning of the study. Mothers signed informed consent 
written in French and explained in local language.
Results
At delivery sHLA-G was measured for all mothers and 
all cord blood samples (n = 165). During the follow-up, 
a total of 445 measurements were performed from 3 to 
12  months distributed as follows: 109/165 at 3  months, 
113 at 6 months, 114 at 9 months and 109 at 12 months. 
Overall, a total of 775 measurements (mother, cord, 3, 
6, 9 and 12 months) were performed. In most cases, an 
HLA-G measurement was missing because the mother 
had not attended a quarterly visit. Only 10 children 
(6.1 %) were present for a single visit.
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Characteristics of the study population
The mean age of the mothers was 26.75 years (SD = 6.37, 
range 16–49). Most women were multi-gravidae (81.2 %, 
n  =  134), and 40  % were suffering from anaemia at 
delivery.
The mean birth weight of newborns was 2,964 grammes 
(SD = 448.31) and 10.9 % (n = 18/165) of children had 
a LBW. Eighty-eight children (53.33 %) were female and 
eighteen children were premature. During the follow-up, 
50.9 % (n = 84/165) of children had at least one malaria 
infection, and 10  % more than two. The most infected 
child had seven infections.
Soluble HLA‑G at delivery
At delivery, 78.2  % of women had detectable levels of 
sHLA-G (n  =  129/165). The mean level in the periph-
eral blood for all women was 19.12 ng/ml (SD =  25.60, 
range 0–132.22). Sixty percent of children (n = 99/165) 
had detectable sHLA-G in cord blood and the mean level 
was 16.22 ng/ml (SD = 26.83, range 0–128.52). A strong 
correlation has been described previously between the 
mother/newborn (cord blood) sHLA-G levels, with a sig-
nificantly higher level in mother’s blood at delivery [24]. 
The sHLA-G level increased gradually before stabilizing 
after 9 months (Fig. 1).
Trajectory groups of HLA‑G
During the first step of analysis, groups of children fol-
lowing the same pattern of sHLA-G have been identified. 
Using the BIC as criteria, the two-group model showed 
a higher BIC than both three- and four-group models. 
The four-group model was selected when compared to 
the three groups (Table  1). In the three-group model, 
16.9  % of the children have high levels of sHLA-G and 
53.8 % remained at low levels whereas the third trajectory 
(29.3  %) was characterized by low levels tending to rise 
after 6  months. When a fourth trajectory was added, a 
new intermediate one appeared starting with very low 
levels until 6  month of age and rapidly rising (Fig.  2; 
Table 1). From three-group model the following pattern 
was constantly identified: one trajectory with low levels 
of sHLA-G (the higher percentage), one with high levels 
(the lower percentage) and an intermediate one. Adding a 
new trajectory led to the same trend with the emergence 
of new intermediate group, representing low percentages 
of the population. To pursue analysis, the three- and the 
four-trajectory models only were used (Table 1).
Effect of covariates on the trajectories
Using the three-group model, placental malaria 
(p = 0.59), parity (p = 0.31), gender (p = 0.95), prema-
turity (p = 0.43), maternal anaemia (p = 0.51) and para-
site density (p =  0.52) have no significant effect on the 
dynamics of sHLA-G. In contrast, LBW appeared to 
be significantly associated with higher levels of sHLA-
G (p  <  10−3). Similarly, detectable sHLA-G level in 
cord blood, or in mother’s peripheral blood at delivery, 
was associated with higher levels of sHLA-G from 3 to 
12  months of life (p  <  10−3 in the both case). Having 
more than one malaria attack during the follow-up was 
significantly associated with higher levels of sHLA-G 
(p = 0.008). In the same way, the higher levels of malaria 
exposure were significantly related to the high levels of 
sHLA-G (p = 0.01).
During multivariate analysis “placental malaria” was 
forced in the model. The results are presented in Table 2. 
LBW, presence of sHLA-G in cord blood or in mater-
nal blood at delivery were significantly associated with 
higher levels of sHLA-G (p  <  10−3). High exposure to 
malaria and having more than one malaria infection dur-
ing the follow-up were significantly associated with high 
levels of sHLA-G (p = 0.001 and p = 0.002, respectively). 
In the final model, the proportions of the groups were 
50.9, 27.2 and 21.9 %, respectively for the low, interme-
diate and high trajectories (Table 1). All these covariates 
have similar effects within each trajectory. As an exam-
ple, children born with a LBW have significantly higher 
sHLA-G levels during their first year of live whatever the 
group they belong (Fig. 3).
Using the four-trajectory model, the same pattern of 
results was obtained. However, the introduction of LBW 
resulted in an increase of the proportion of children 
belonging to the high trajectory from 8 to 17  %, while 
the intermediate-high trajectory decreased from 22 to 
15 %, consistent with a low stability of the four-trajectory 
model (Table 1).
In the third step of analysis, the role of placental 
malaria, parity, maternal anaemia, presence of sHLA-G 
Fig. 1 Evolution of the mean level of sHLA‑G in newborns in the first 
year of life
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in cord blood and LBW as predictor to belong to either 
group, were examined. Among them, for the three-group 
model only the presence of sHLA-G in cord blood was 
associated with a significantly higher probability to 
belong to the high or intermediate trajectory (OR = 22.8 
and OR  =  6.1, respectively). Accordingly, a child born 
with sHLA-G in cord blood would have a probability of 
76.25, 20.40 and 3.35 % to belong to the high, intermedi-
ate or the low trajectory, respectively.
When the same analysis was performed using the four-
group model, convergence was not achieved, reinforcing 
the instability of this model. Taken together, the results 
are consistent with the existence of three-trajectory 
model. With this model 97  % of children from the low 
trajectory, 91.7 and 83  % of children from respectively 
the intermediate and high trajectories were classified as 
belonging to these groups with a posterior probability 
greater than 70 %.
Table 3 shows the characteristics of the children and of 
their mothers in the three groups. LBW children seemed 
to be more present in the “high trajectory” than in others. 
Children in this group were born to mothers with detect-
able sHLA-G at delivery, and the majority had sHLA-G 
in cord blood.
Table 1 Distribution of newborns in the two-, three- and four-group models
a A lower BIC indicates a better fitting
b With no covariate
c With all significant covariates in multivariate analysis
Trajectories Model BICa Distribution of newborns in groups
High (%) Intermediates… (%) Low (%)
2 Emptyb 1494,644 27.2 72.78
Fullc 24.2 75.8
3 Empty 1464,333 16.9 29.3 53.8
Full 21.9 27.2 50.9
4 Empty 1438,894 7.7 21.9 19.9 50.5
Full 13.9 15.7 23.1 47.3
Fig. 2 Trajectories of soluble HLA‑G for the two‑, three‑ and four‑group models
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Discussion
The present work is complementary to study of Sadissou 
et  al., describing the evolution of sHLA-G in a popula-
tion of African infants [24]. In the first study, a strong 
correlation has been shown between mother and cord 
blood levels of sHLA-G at delivery, as well as an asso-
ciation between LBW and high level of sHLA-G during 
the first year of life. In addition, high levels of sHLA-G 
were associated with an increase of the incidence ratio 
of malaria during the follow-up, but the total number of 
malaria infections during the follow-up was not associ-
ated with the level of sHLA-G.
The present analysis, confirms these results, and pro-
vides new understanding by identifying new determi-
nants of sHLA-G evolution. Indeed, although in the first 
study, the level of sHLA-G increased the risk of infection 
in the following quarter, any association has not been 
highlighted between the level of sHLA-G and the over-
all number of malaria infections during the follow-up. In 
this complementary analysis, this association is strongly 
significant. The difference between these two results 
could be due to the complexity of the effect of malaria 
infection that cannot be pointed out under the hypothesis 
that all children belong to the same homogeneous popu-
lation. Using latent class approach allows hypothesizing 
that distinct subpopulations of children are presents in 
the overall population, each with its own characteristics, 
with distinctive sHLA-G evolutions. This approach per-
mitted us to explore more precisely the complex associa-
tion between malaria and HLA-G.
The mechanisms by which HLA-G gene expression is 
regulated are only partially understood [37]. Concern-
ing infections, HIV or hepatitis, infected patients have 
higher level of sHLA-G, and it has been suggested that 
Table 2 Risk factors of soluble HLA-G evolution from 3 to 12 months in 165 newborns at Tori Bossito, 2007–2010: latent 
class analysis
a Univariate estimation represents the coefficient of the univariate regression
b Adjusted estimation is obtained after the multivariate analysis
c Results were the same, when “HLA-G in cord blood” was replaced by “HLA-G in maternal peripheral blood”. Presence of sHLA-G in maternal blood is highly 
significantly related to high level of HLA-G in newborns during the first 12 months. We did not introduce together the two covariates in the model because they are 
highly correlated [24]
Covariates Univariate estimationa Adjusted estimationb 95 % CI p value
Intercept – 0.58 0.28–0.88 <10−3*
HLA‑G in cord blood
 No – –
 Yes 0.60 0.42 0.15–0.70 0.002c*
Low birthweight (<2500 g)
 No – –
 Yes 0.62 0.86 0.42–1.29 <10−3*
Malaria infections
 ≤1 – –
 >1 0.20 0.33 0.11–0.54 0.003*
Malaria exposure (quartiles)
 Low – –
 Middle 0.33 0.43 0.19–0.68 0.001*
 High and very high 0.32 0.35 0.13–0.56 0.002*
Placental malaria
 No – –
 Yes –0.07 –0.12 –0.35–0.11 0.36
Fig. 3 Effect of low birth weight on the evolution of trajectories 
groups from 3 to 12 months
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these levels induce tolerance and contribute to immune 
evasion of virus [38–42]. Although, to date, such hypoth-
esis has not been clarified for malaria; it could be hypoth-
esized that the same phenomenon occurs during malaria 
infection leading to immune evasion. Indeed, P. falcipa-
rum could upregulate the HLA-G secretion through the 
stimulation of cytokines such as IL-10 and IFN-γ. HLA-G 
is known to inhibit the function of T, NK and B cells 
through direct interaction with ILT2. Recently, Naji et al. 
showed that HLA-G inhibits B cell proliferation, differ-
entiation, and immunoglobulin (Ig) secretion in both T 
cell–dependent and –independent models of B cell acti-
vation. HLA-G also acts as a negative B cell regulator 
in modulating B cell antibodies secretion in a xenograft 
mouse model [43]. Taken together all these arguments 
are consistent with the existence of a complex interac-
tion between HLA-G, immunity and P. falciparum infec-
tion, leading to a lower B cell response. As IgG antibodies 
play a pivotal role in anti-malarial protection [44–46], the 
inhibition of IgG specifically directed against P. falcipa-
rum mediated by HLA-G, not only allows the parasite to 
escape the immune system but also is responsible of the 
higher susceptibility to infection showed previously.
However, other factors could influence HLA-G secre-
tion during malaria infection. It has been shown that 
hypoxia could play a role in HLA-G regulation during 
pregnancy [47], in some cancer [48] but also in more 
physiologic but extreme life conditions like altitude [49]. 
Tissue hypoxia resulting from decreased microcircula-
tory flow due to parasite sequestration and endothelial 
dysfunction contributes to the pathogenesis of malaria in 
children [50, 51]. The results could be consistent with the 
fact that malaria related hypoxia is already present very 
early in life and associated with an increase of sHLA-G 
levels, and consequently strengthening the inhibition of 
immunity.
More than 60  % of the children born with a LBW 
belong to the high and intermediate trajectories. It is 
widely accepted that birth weight is a key indicator of 
fetal and neonatal health [52–54] and overall 60–80  % 
of infants who die during the neonatal period are chil-
dren born with LBW [55]. The association between LBW 
and HLA-G has already been shown in this same cohort 
using mixed model [24]. However, the present approach 
allows pointing out a very interesting aspect, which has 
not been demonstrated by previous analysis. Indeed, 
children born with detectable HLA-G in their cord 
blood have a greater probability to belong to the higher 
or intermediate trajectories than other children, and 
hence be concerned by LBW. Considering the frailty of 
LBW children, the detection of such high-risk individuals 
could have huge public health consequences. Taking into 
account the strong correlation between sHLA-G in cord 
blood and in mother’s blood at delivery, the mother’s 
Table 3 Distribution of 165 mother/child pairs in the different groups, 2007–2010
Covariates High trajectory
(n = 28/165)
Intermediate trajectory
(n = 46/165)
Low trajectory
(n = 91/165)
Newborns (165)
Level of sHLA‑G
 3 months 3.29 0.58 0.14
 6 months 3.21 1.35 0.31
 9 months 3.78 2.32 0.33
 12 months 3.88 2.47 0.30
Gender
 Female 17 (60.71 %) 24 (52.17 %) 47 (51.65 %)
 Male 11 (39.28 %) 22 (47.83 %) 44 (48.35 %)
Birth weight 2894.52
(SD = 369.30)
3076.63
(SD = 500.10)
2928.57
(SD = 437.05)
Low birth weight 17.86 % (n = 5) 13.04 % (n = 6) 7.69 % (n = 7)
Preterm 10.71 % (n = 3) 6.52 % (n = 3) 13.19 % (n = 12)
Detectable sHLA‑G in cord blood 96.43 % (n = 27) 73.91 % (n = 34) 41.76 % (n = 38)
Number of malaria infections during the follow‑up 1.11
(SD = 1.31)
0.96
(SD = 1.46)
1.13 (SD = 1.41)
Mothers (165)
Age (years) 26.54 (SD = 6.08) 28.15 (SD = 6.06) 25.78 (SD = 6.48)
Parity 25.00 % (7) 13.04 % (6) 19.78 % (18)
Placental malaria 21.43 % (6) 26.09 % (12) 36.26 % (33)
Detectable sHLA‑G in peripheral maternal blood 100.00 % (28) 93.48 % (43) 63.74 % (58)
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sHLA-G level could be considered as a potential marker 
of high-risk newborn. Soluble HLA-G has already been 
proposed as predictor of in  vitro fecundation outcome 
[56], but also as biomarker of allergy [57], allograft and 
cancers [58, 59]. A follow-up of pregnant women and of 
their offspring over 2  years is now ongoing in Benin to 
test whether the sHLA-G level early in pregnancy is also 
correlated with HLA-G level in cord blood or with infec-
tious morbidity during the first 2 years of life.
Latent class analysis approach is more and more fre-
quently used in biomedical research [60]. It is an exten-
sion of mixed models that assume the presence of several 
groups of subjects (latent groups) sharing a particular 
evolution trajectory of some attribute. This approach 
allows a better understanding of the phenomenon under 
study and the formulation of new questions or hypoth-
eses [61, 62]. This methodology is part of mixture mod-
elling, a wide data analysis approach allowing studying 
unobserved heterogeneity in a population [60]. The 
question of the number of trajectories remains of great 
importance and to date, there is no single statistical 
test to determine the correct number of latent classes 
[63]. The selection of the best model needs to take into 
account statistical measures of model fitting but also the 
interpretation of the output, in particular the relevance 
of the different groups, based on the literature or the 
expert’s knowledge. BIC was used as statistical criteria 
although others can be proposed. Bootstrap Likelihood 
Ratio test (BLRT) has been proposed as being more pow-
erful. However, BLRT needs an increased computation 
time and finally the authors recommended using BIC as 
the first step [64]. In the data, using BIC would lead to 
choose a model with four trajectories instead of three. 
Both model have the same interpretation since the two 
intermediate trajectories in the four-group model share 
the same evolution, i.e. high level trajectory, low level tra-
jectory and intermediate group(s) starting with low levels 
of sHLA-G and then growing up. However, models with 
more than three trajectories seem to present a lower sta-
bility. Finally, to deal with the possibility and complexity 
of these population mixture models, it could be of inter-
est to pursue this exploration by using different methods 
in different populations.
A genetic association between HLA-G and malaria has 
already been pointed out. Indeed, it has been shown that 
some polymorphisms of the HLA-G 3’UTR were asso-
ciated with variable risk of infection [22], but also with 
antibody responses against P. falciparum. These asso-
ciations have been identified in another population from 
Senegal. It has also been demonstrated that a strong 
molecular signature of balancing selection at HLA-G 
5’URR exist and that this region may certainly be the 
direct target of selection [65]. These results strengthen 
the interest of this gene and of sHLA-G as potentially 
involved in differential susceptibility to malaria.
Conclusion
Summary, this study allowed a better understanding of 
the complex interaction between HLA-G and malaria 
infection and pointed out the potential interest of sHLA-
G as marker of frailty.
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